ArticleCancer biology & medicine2024
Cervical cancer prevention in China: where are we now, and what's next?
Article in Cancer biology & medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Changes in HPV vaccine hesitancy and influencing factors among female university students in China: A national repeated study.Human vaccines & immunotherapeutics · 2026Article
- Article
- Analyzing and forecasting global cervical cancer burden based on WHO's elimination strategy: insights and projections from a 1990-2021 global burden of disease (GBD) study covering 204 countries and territories.Journal of advanced research · 2026Article
- Urban-rural disparities in HPV prevalence and genotype distribution: a large-scale cervical cancer screening study in Xi'an, China.BMC infectious diseases · 2026Article
- Real-World Performance of HPV DNA-Based Screening in Health Resource-Limited Areas of China: A Multicenter Implementation Study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026Article
- Minimal benefit of co-testing over HPV primary screening with cytology triage from resource-limited settings in China.Communications medicine · 2026Article
- Testing menstrual blood for human papillomavirus during cervical cancer screening in China: cross sectional population based study.BMJ (Clinical research ed.) · 2026Observational
- Dual-dimensional profiling of host genomic variations and HPV integration in PD-L1-stratified cervical cancer via Oxford Nanopore Technology.Journal of translational medicine · 2026Article
- Burden and temporal trends of female-specific cancers in China: A systematic analysis of the 2023 global burden of disease study.PloS one · 2026Article
- Factors associated with cervical cancer screening participation in Southwest China: a retrospective database-based cross-sectional study.Frontiers in medicine · 2026Article
- Risk-stratified surveillance after LEEP: a nomogram integrating HPV persistence, margin status, and clinical factors to predict CIN2+ recurrence.Frontiers in oncology · 2026Article
- Assessing the influence of male vaccination on cervical cancer elimination in China under different vaccination coverage scenarios: A modeling study.Human vaccines & immunotherapeutics · 2025Review
- Evaluation of an intelligent digital platform for population management in cervical cancer screening.Cancer biology & medicine · 2025Observational
- Global burden of cervical cancer: current estimates, temporal trend and future projections based on the GLOBOCAN 2022.Journal of the National Cancer Center · 2025Article
- Age-related distribution of human papillomavirus genotypes in women with cervical squamous cell carcinoma from Linyi, China, 2015-2023.Virology journal · 2025Article
- Epidemiological study of HPV infection in 24,588 rural women in Luonan, China.Gynecologic oncology reports · 2025Article
- Integrated HPV Testing, TCT, and Colposcopic VIA/VILI Improves Detection Rate for HSIL and Cervical Cancer: A Retrospective Cohort in China.International journal of women's health · 2025Article
- Evolving landscape of female cancers along with attributable risk factors in China from 1990 to 2021, and projections to 2040.Frontiers in public health · 2025Article
- Cost-effectiveness of cervical cancer screening and HPV vaccination: a Markov model from the healthcare payer perspective.Frontiers in public health · 2025Article
- A real-world, cross-sectional, and longitudinal study on high-risk human papillomavirus genotype distribution in 31,942 women in Dongguan, China.Frontiers in public health · 2024Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.